National Institute on Drug Abuse; Notice of Closed Meetings, 58320 [2013-22992]
Download as PDF
<![CDATA[
58320
Federal Register / Vol. 78, No. 184 / Monday, September 23, 2013 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS, GENERATION 3 COHORT AND OMNI GROUP 2 COHORT
Number of
responses per
respondent
Number of
respondents
Type of respondent
I. PARTICIPANT COMPONENTS—ANNUAL FOLLOW-UP
A. Records Request .................................................................................
B. Health Status Update ...........................................................................
Average time
per response
(in hours)
Total annual
burden hour
3212
3212
1
1
15/60
15/60
803
803
SUB-TOTAL: PARTICIPANT COMPONENTS ..................................
II. NON-PARTICIPANT COMPONENTS—ANNUAL FOLLOW-UP
A. Informant contacts ...............................................................................
B. Records Request .................................................................................
* 3212
........................
........................
1606
160
1060
1
1
10/60
15/60
27
265
SUB-TOTAL: NON-PARTICIPANT COMPONENTS ........................
1220
........................
........................
292
* Number of participants as reflected in Rows I.A. and I.B. above.
SUMMARY OF 3 TABLES COMBINED—TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of respondents
Number of responses per
respondent
Participants ......................................................................................................
Non-Participants ..............................................................................................
5564
3816
1
1
36/60
14.5/60
3344
920
Totals ........................................................................................................
9380
........................
........................
4264
Type of respondent
Average time
per response
(in hours)
Total annual
burden hour
(NOTE: reported and calculated numbers differ slightly due to rounding.)
Lynn Susulske,
NHLBI Project Clearance Liaison, National
Institutes of Health.
Michael Lauer,
Director, DCVS, National Institutes of Health.
[FR Doc. 2013–23060 Filed 9–20–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
emcdonald on DSK67QTVN1PROD with NOTICES
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 USC,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel GOMED:
Grand Opportunity in Medications
Development for Substance-Related
Disorders (U01).
Date: October 15, 2013.
VerDate Mar<15>2010
20:16 Sep 20, 2013
Jkt 229001
Time: 9:00 a.m. to 11:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Washington, DC/
Bethesda, 7301 Waverly Street, Bethesda, MD
21045.
Contact Person: Jose F. Ruiz, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, Room 4228, MSC 9550,
6001 Executive Blvd., Bethesda, MD 20892–
9550, (301) 451–3086, ruizjf@nida.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel Strategic
Alliances for Medications Development to
Treat Substance Use Disorders (R01) (PAS–
12–122).
Date: October 15, 2013.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Washington, DC/
Bethesda, 7301 Waverly Street, Bethesda, MD
21045.
Contact Person: Jose F. Ruiz, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, Room 4228, MSC 9550,
6001 Executive Blvd., Bethesda, MD 20892–
9550, (301) 451–3086, ruizjf@nida.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Medications Development Centers of
Excellence Cooperative Program.
Date: October 15–16, 2013.
Time: 2:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Washington, DC/
Bethesda, 7301 Waverly Street, Bethesda, MD
21045.
Contact Person: Jose F. Ruiz, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Drug Abuse, NIH, Room 4228, MSC 9550,
6001 Executive Blvd., Bethesda, MD 20892–
9550, (301) 451–3086, ruizjf@nida.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 17, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–22992 Filed 9–20–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
E:\FR\FM\23SEN1.SGM
23SEN1
]]>Agencies
[Federal Register Volume 78, Number 184 (Monday, September 23, 2013)]
[Notices]
[Page 58320]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-22992]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
USC, as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable materials, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel GOMED: Grand Opportunity in Medications Development
for Substance-Related Disorders (U01).
Date: October 15, 2013.
Time: 9:00 a.m. to 11:00 a.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Garden Inn Washington, DC/Bethesda, 7301 Waverly
Street, Bethesda, MD 21045.
Contact Person: Jose F. Ruiz, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse, NIH,
Room 4228, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550,
(301) 451-3086, ruizjf@nida.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel Strategic Alliances for Medications Development to
Treat Substance Use Disorders (R01) (PAS-12-122).
Date: October 15, 2013.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Garden Inn Washington, DC/Bethesda, 7301 Waverly
Street, Bethesda, MD 21045.
Contact Person: Jose F. Ruiz, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse, NIH,
Room 4228, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550,
(301) 451-3086, ruizjf@nida.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Medications Development Centers of Excellence
Cooperative Program.
Date: October 15-16, 2013.
Time: 2:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Garden Inn Washington, DC/Bethesda, 7301 Waverly
Street, Bethesda, MD 21045.
Contact Person: Jose F. Ruiz, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse, NIH,
Room 4228, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550,
(301) 451-3086, ruizjf@nida.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: September 17, 2013.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-22992 Filed 9-20-13; 8:45 am]
BILLING CODE 4140-01-P
